Am­gen aug­ments Asia foothold by tak­ing over Astel­las joint ven­ture in Japan

Cal­i­for­nia-based Am­gen, which does the bulk of its busi­ness in the Unit­ed States, made its am­bi­tion to rein­vig­o­rate its growth prospects by ex­pand­ing its pres­ence in Asia clear at the side­lines of the JP Mor­gan health­care con­fer­ence in San Fran­cis­co ear­li­er this month.

The Thou­sand Oaks-based com­pa­ny on Thurs­day ex­e­cut­ed its plan to dis­solve the joint ven­ture with Astel­las — cre­at­ed in 2013 — to op­er­ate the unit in­de­pen­dent­ly in Japan. With its rapid­ly ag­ing pop­u­la­tion, the re­gion rep­re­sents an ap­peal­ing mar­ket for Am­gen’s os­teo­poro­sis treat­ments Pro­lia and Eveni­ty as well as a cho­les­terol-low­er­ing in­jec­tion Repatha.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER